Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intralipid, 20% Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Mechanisms of Insulin Resistance in Humans

NCT00330967
View directory record Official record
Conditions
Inflammation, Insulin Resistance
Interventions
20% Intralipid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454
View directory record Official record
Conditions
Obesity, Leptin Resistance
Interventions
Saline, Intralipid, Water, oral fat, Heparin
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

NCT00826020
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions
Omegaven™
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 3, 2026, 7:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 3, 2026, 7:41 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

NCT04328337
View directory record Official record
Conditions
Obesity
Interventions
Intralipid, 20% Intravenous Emulsion, Placebos
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Up to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Park Ridge, Illinois • Indianapolis, Indiana • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 3, 2026, 7:41 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

NCT07179003
View directory record Official record
Conditions
Breast Abscess
Interventions
Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy
Procedure · Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns

NCT03857646
View directory record Official record
Conditions
Prematurity
Interventions
Intralipid, 20% Intravenous Emulsion, Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Days to 8 Days
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Not applicable Interventional

Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants

NCT01062815
View directory record Official record
Conditions
Cholestasis, Prematurity, Gastroschisis, Intestinal Atresia, Necrotizing Enterocolitis
Interventions
Parenteral Nutrition
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 22, 2015 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

NCT02357576
View directory record Official record
Conditions
Cholestasis
Interventions
Intralipid 20% I.V. Fat Emulsion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 1 Year
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

NCT00111189
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Paliperidone Palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
18
States / cities
Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Early Phase 1 Interventional

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy

NCT01306838
View directory record Official record
Conditions
Short Bowel Syndrome, Necrotizing Enterocolitis, Small Intestine Perforation
Interventions
MicroLipid and fish oil, Routine care
Dietary Supplement · Other
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 3, 2026, 7:41 PM EDT
Not listed No phase listed Observational

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

NCT05439174
View directory record Official record
Conditions
End-stage Renal Disease, Malnutrition; Protein
Interventions
Intradialytic Parenteral Nutrition
Other
Lead sponsor
Patient Care America
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Phase 1 Interventional

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NCT00088647
View directory record Official record
Conditions
Neoplasms
Interventions
MST-997
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2006 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Not applicable Interventional Results available

Intravenous Fat Emulsions and Premature Infants

NCT01096446
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperglycemia
Interventions
Intravenous Fat Emulsions
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
1 Day to 2 Days
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Dose Fat-Induced Insulin Resistance

NCT03479671
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity
Interventions
Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 44 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

NCT01515423
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq., PP1M 150 mg eq.
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
24
States / cities
Little Rock, Arkansas • Glendale, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates

NCT03387579
View directory record Official record
Conditions
Cholestasis of Parenteral Nutrition
Interventions
Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities

NCT02240498
View directory record Official record
Conditions
Abscess
Interventions
Methylene Blue, 20% I.V. Fat Emulsion, Insertion of optical fiber, Laser illumination, 5 minutes, Laser illumination, 10 minutes, Laser illumination, 15 minutes, Laser illumination, 20 minutes, Laser illumination, 25 minutes, Laser illumination, 30 minutes, Optical spectroscopy measurement
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

NCT04555044
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
0 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • New Haven, Connecticut • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 3, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

NCT03563222
View directory record Official record
Conditions
Malnutrition, Child
Interventions
Smoflipid, Intralipid, 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
3 Months to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 3, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Training Effects on Skeletal Muscle Fatty Acid Metabolism

NCT00786487
View directory record Official record
Conditions
Healthy Volunteers
Interventions
20% lipid infusion, glycerol
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 3, 2026, 7:41 PM EDT